Tirzepatide Peptide

Product Specifications

CAS: 2023788-19-2

Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 diacid-γGlu-OEG-OEG linker)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: 4813.45 Da

Amino Acid Length: 39 residues

Receptor Targets: GIP receptor and GLP-1 receptor (dual agonist)

Purity: 99%+ (verified by HPLC)

Appearance: White to off-white lyophilized powder

Form: Lyophilized (freeze-dried)

Storage

Compounded tirzepatide vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted tirzepatide peptide should be kept at -20°C for long-term storage or 2-8°C for short-term storage. Once reconstituted with bacteriostatic water, tirzepatide should be refrigerated at 2-8°C and used within 28 days for optimal stability. Do not freeze reconstituted solutions. Always follow proper storage guidelines to maintain product integrity for research applications.

Solubility

Tirzepatide compound is soluble in bacteriostatic water and sterile saline. Recommended reconstitution concentration is 1-5 mg/mL. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

Tirzepatide is intended for research purposes only and is not approved for human use outside of FDA-approved branded formulations.

Tirzepatide Weight Loss Results and Body Composition Benefits

• In the landmark SURMOUNT-1 clinical trial, participants without diabetes achieved mean body weight reductions of 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg over 72 weeks. Between 89% and 91% of participants receiving the 10 mg or 15 mg tirzepatide dosage achieved a clinically meaningful weight reduction of 5% or more.
• When comparing semaglutide vs tirzepatide head-to-head in the SURMOUNT-5 trial, tirzepatide demonstrated superior tirzepatide weight loss at 72 weeks with a mean reduction of 20.2% compared to 13.7% for semaglutide. This is the key difference between semaglutide and tirzepatide in clinical outcomes.
• Tirzepatide treatment resulted in fat mass reduction approximately three times greater than lean mass reduction, improving overall body composition. In the SURMOUNT-4 continuation trial, participants who stayed on tirzepatide achieved a total mean weight loss of 26% from baseline.
• Research confirms that tirzepatide side effects during weight loss trials were predominantly gastrointestinal (nausea, decreased appetite) and generally mild to moderate. No significant increase in serious adverse events or all-cause mortality was observed across multiple trials.

How Does Tirzepatide Work for Glycemic Control and Appetite Suppression?

• Tirzepatide is a dual GIP/GLP-1 receptor agonist, the first compound to target both incretin pathways. This dual mechanism produces stronger effects on blood glucose regulation and weight reduction than either pathway alone. In a meta-analysis of 14 randomized controlled trials with 11,158 patients, tirzepatide reduced HbA1c by up to 9.84% and outperformed placebo, GLP-1 receptor agonists, and insulin across all measured parameters.
• Research shows tirzepatide improves insulin sensitivity and insulin secretory responses to a greater extent than semaglutide alone, with lower post-meal insulin and glucagon concentrations. This explains why switching from semaglutide to tirzepatide may provide additional metabolic benefits in certain research protocols.
• Decreased appetite was reported in 3.8% to 18.9% of participants across tirzepatide dosage groups, with all three doses producing greater appetite suppression than comparators. Studies indicate tirzepatide suppresses appetite and food intake through centrally mediated pathways, contributing to its weight loss effects.

Tirzepatide Benefits for Cardiovascular Health and Heart Failure

• The SUMMIT trial demonstrated that tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure by 38% (hazard ratio 0.62) in patients with heart failure with preserved ejection fraction and obesity, over a median follow-up of 104 weeks.
• Heart failure events requiring hospitalization or IV medications were reduced by 59% (hazard ratio 0.41) in tirzepatide-treated patients compared to placebo. Participants also achieved 11.6% body weight reduction at 52 weeks, with significant improvements in 6-minute walk distance (+18.3 meters) and quality-of-life scores.
• Is tirzepatide safe for cardiovascular research? The data supports a favorable safety profile. No difference in serious adverse events or all-cause mortality was found between tirzepatide and placebo groups across multiple large-scale clinical trials. Does tirzepatide cause hair loss? Some reports exist, but clinical trial data has not identified hair loss as a statistically significant tirzepatide side effect.

Tirzepatide Dosage Chart for Research

The tirzepatide dosage used in clinical research follows a structured escalation protocol. Understanding the compounded tirzepatide dosage schedule is essential for proper research design:

• Starting dose: 2.5 mg once weekly for 4 weeks (initiation phase for tolerability assessment).
• Dose escalation: Increase by 2.5 mg every 4 weeks as tolerated. Tirzepatide dosing for weight loss in clinical studies used escalation to 5 mg, 10 mg, or 15 mg weekly.
• Maintenance doses studied: 5 mg, 10 mg, or 15 mg once weekly via subcutaneous injection. Higher doses demonstrated greater weight loss and glycemic improvements.
• Microdosing tirzepatide: Some research protocols explore sub-therapeutic doses below 2.5 mg weekly. Refer to a microdosing tirzepatide chart specific to your study design for guidance on incremental dosing.

Tirzepatide dosing frequency in all major clinical trials was once weekly via subcutaneous injection. The tirzepatide half life supports weekly administration, maintaining therapeutic levels between doses. For researchers asking how many units is 2.5 mg of tirzepatide, this depends on the reconstitution concentration used.

Research Protocol Notes

Compounded tirzepatide is supplied as a lyophilized (freeze-dried) powder to ensure stability during transport. For experimental protocols, the peptide must be reconstituted using a sterile solvent, most commonly bacteriostatic water. Researchers should introduce the diluent slowly down the side of the vial to prevent damaging the peptide structure. Where to inject tirzepatide in research settings is typically the subcutaneous tissue of the abdomen, thigh, or upper arm, rotating injection sites between administrations. Use our tirzepatide reconstitution calculator for precise dilution measurements.